Skip to main content
. Author manuscript; available in PMC: 2016 Aug 2.
Published in final edited form as: Mol Pharm. 2016 Feb 1;13(3):839–851. doi: 10.1021/acs.molpharmaceut.5b00763

Figure 7.

Figure 7

Effect of CQ pretreatment on the accumulation of [3H]pitavastatin in human SCH. (A) Time-dependent accumulation of [3H]pitavastatin (1 μM) in human SCH. Data represent the mean ± SD in triplicate from a single hepatocyte donor. (B) Model-estimated fold change and associated SE in [3H]pitavastatin accumulation vs CTL in human SCH pretreated with 10 μM CQ or CTL for 5 h. Following pretreatment in culture medium containing CQ (10 μM) or control, human SCH were rinsed three times with HBSS, and [3H]pitavastatin accumulation (1 μM, 0.5 min) was determined. Fold change and SE were estimated by a generalized linear mixed model, as described in the Experimental Section (n = 3 in triplicate). * indicates a statistically significant difference (p < 0.05) vs CTL.